Generex Biotechnology Corp. (GNBT) spins out, stock points higher
Posted on: September 15th, 2011Written by:
Generex Biotechnology Corp. (OTCBB: GNBT) saw its shares gain 8.7% to 9.89 cents, as Thursday’s markets closed, on news of the spinout of one of its subsidiaries. Volume for the stock was 1.3 million shares, nosing out its full-day average.
A news release dated Sept. 15 announced that the company, based in Worcester, Mass., provided an update on the status of the previously announced spinout of its wholly-owned subsidiary, Antigen Express, Inc.
The Company is in the midst of a detailed and comprehensive review of several transaction opportunities, including both shell companies and operating biotech companies with synergistic intellectual properties, in each case Securities and Exchange Commission registrants and Depository Trust Company eligible companies, into which Antigen Express will be merged.
Generex CEO Mark Fletcher, “We are undertaking our due diligence examination of available alternatives with a view to identifying an appropriate transaction for the Antigen Express spinout.
“We will proceed with expedition to negotiate an agreement with the target company, complete the merger of Antigen Express into that company, and conduct an initial fund raising. If the merger and the initial fund raising are successful, we will then seek a listing of the merged company’s stock on a national stock exchange.”
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.
Phototron Holdings (PHOT) boosts sales, stock leaps
Posted on: September 15th, 2011Written by:
Phototron Holdings (OTCBB: PHOT) shares climbed 138.5% to 31 cents on word of exciting sales figures. Volume for the stock topped 25,000, or at least double its all-day average.
A news release put out Sept. 7 revealed that the company had increased sales by more than 78% during August, entering the second month of its new direct selling business model. August’s strong performance represented $107,000 of unaudited sales compared to approximately $60,000 of unaudited sales in July.
Phototron’s new direct selling business model will help expand Phototron’s future sales capabilities to harness the untapped demand for its innovative turn-key hydroponic gardening system.
The same release quoted CEO Doug Braun thus: “We are extremely pleased with Phototron’s results in our second full month after implementing our new business model and strategic growth initiatives.
“Significant increases in both sales and Phototron’s new affiliates demonstrate that our product and business opportunity are attractive to our target audience. In transition periods, it typically takes time to gather momentum. Now that Phototron is starting to see positive results we are confident that we will continue to see accelerated growth as we begin to focus our energies on leveraging our exciting products and new business model to consumers across the US and worldwide.”
The new direct sales model, initiated in June, represents Phototron’s new direct sales initiatives, which are expected to serve both the $30-billion home gardening market and the $1.7-billion medical marijuana community.
Phototron Holdings, Inc., based in Woodland Hills, Calif., designs and manufactures cutting-edge indoor mini-greenhouses capable of growing herbs, vegetables, flowers, fruits and terrestrial plants stronger and faster than traditional farming methods.
Bioheart Inc. (BHRT) has breakout day over FDA OK
Posted on: September 14th, 2011Written by:
Bioheart Inc. (OTCBB: BHRT) leaped 15.3% to 8.3 cents Wednesday on word of a clinical program the company was engaging in, using adipose cells. Volume for the stock topped 8.1 million near Wednesday’s close.
A news release issued Sept. 14 declared that the company out of Sunrise, Florida announced that they will begin a U.S. clinical program called the ANGEL trial utilizing adipose derived cells or LipiCell for congestive heart failure patients. Using the clinical data from a Phase I/II trial in Mexico and preclinical studies, Bioheart will apply to the Food and Drug Administration (FDA) to begin a Phase I study in the US.
In collaboration with the Regenerative Medicine Institute of Tijuana, Mexico, six congestive heart failure patients have been successfully treated in a Phase I/II trial at Hospital Angeles Tijuana.
The therapy involves the use of stem cells derived from the patient’s own fat (adipose tissue) obtained using liposuction. These patients have demonstrated on average, an absolute improvement of 13 percentage points in ejection fraction and an increase of 100 meters in their six-minute walk distance.
The U.S. ANGEL trial design and results from the Mexico trial were presented by Bioheart’s Chief Scientific Officer, Kristin Comella at the Stem Cells USA & Regenerative Medicine Congress in Boston this week. She was quoted in the same release as saying, “Safety and efficacy have been successfully demonstrated in the trial at Hospital Angeles and we are looking forward to beginning one of the first U.S. trials using adipose derived cells for congestive heart failure patients.”
Bioheart is committed to maintaining our leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues.
Coldwater Creek Inc. (CWTR) shares vault on CEO stock buy
Posted on: September 14th, 2011Written by:
Coldwater Creek Inc. (Nasdaq: CWTR) shares spiked 14.8% to $1.63 Wednesday approaching noon ET, on news Tuesday of a stock purchase by its CEO. Volume for the stock topped two million shares, compared to an all-day average of 887,000.
An article posted Sept. 13 on the site Seeking Alpha mentioned that in recent days Dennis Ponce purchased over 600,000 shares at an average price of around 90 cents. The story also said pointed out that Coldwater Creek has seen quarterly net sales decrease to $181.4 million compared to $253 million in the same quarter in 2010.
Gross profit margins tightened for the quarter as well. Gross profit came in at $45.3 million for the quarter or 25% of net sales, compared with $84.7 million, or 33.4% of net sales in the same quarter in 2010.
The piece in Seeking Alpha added the company recently announced a three-part plan to turn it around, the key elements of which consist of a comprehensive brand marketing campaign, retail store optimization and a merchandising revitalization plan.
Coldwater Creek is a leading specialty retailer of women’s apparel, gifts, jewelry, and accessories founded in 1984 and headquartered in Sandpoint, Idaho.
RXi Pharmaceuticals Corporation (RXII) clinical trials to continue, shares jump
Posted on: September 12th, 2011Written by:
RXi Pharmaceuticals Corporation (Nasdaq: RXII) shares gained 12% to $1.12 Monday, after favorable news about the company’s breast cancer vaccine trial. Volume for the stock exceeded 3.5 million shares, compared to a daily average of 722,000.
A story published Monday in Boston Business Journal revealed that the U.S. Food and Drug administration has cleared the way for the start of Rxi to launch its Phase 3 trial studying a potential vaccine for a certain type of breast cancer.
If successful, the vaccine would provide an alternative for women who have low to intermediate expression of the HER2 mutation, and are not eligible for the blockbuster drug Herceptin, made by Swiss drug maker Roche AG.
The FDA has now lifted a partial clinical hold the agency put on the chemistry, manufacturing and controls associated with the vaccine trial.
Worcester, Mass.-based RXi acquired the potential vaccine, called NeuVax, when it bought Scottsdale, Ariz.-based Apthera. As part of the deal, Apthera’s shareholders initially received approximately 4.8 million shares of Worcester, Mass.-based RXi’s common stock, worth $7.2 million at the time, on March 30. The deal closed in April. Apthera’s stockholders will also be entitled to contingent payments tied to clinical, regulatory and commercial milestones connected to NeuVax.
The partial clinical hold was placed on the vaccine candidate before it was acquired by RXi, and its lifting will allow the company to start its Phase 3 trial in the first half of 2012. The study is expected to include about 100 trial sties in the U.S., Canada and Europe.
Single Touch Systems Inc. (SITO) jumps on patent news
Posted on: September 12th, 2011Written by:
Single Touch Systems Inc. (OTCBB: SITO) saw its shares zoom higher by 11.6% to 48 cents Monday, on favorable patent tidings. Volume for the stock topped 147,000.
A news release dated Sept. 12 stated that company was issued U.S. Patent 8,015,307 for “System and Method for Streaming Media,” on September 6, another patent in the field of streaming media that further strengthens an already robust streaming media patent portfolio.
Recently, Single Touch sent “Letters of Notification” to Hulu who is jointly owned by Comcast (NASDAQ: CMCSA), News Corp (NASDAQ: NWSA) and Disney (NYSE: DIS) and to Netflix , Inc. (NASDAQ: NFLX), advising that Single Touch is the holder of issued US Streaming Media patents, which include US Patents 7,054,949; 7,191,244 and 7,689,706. The letters also noted the impending issuance of US Patent 8,015,307.
Single Touch Systems has filed and has been awarded more than 15 U.S. patents related to Streaming Media, Advertising and Abbreviated Dialing Codes.
In the release, Single Touch Chairman Anthony Macaluso said, “After years of establishing ourselves as a pioneer in mobility, and cementing our IP position, it has become increasingly important for us to take the steps necessary to protect what we have already established with the assistance of law firms such as Polsinelli Shughart and McKool Smith.”
Single Touch Systems Inc. is an innovative mobile solutions provider serving retailers, advertisers and brands.
